Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03439462
Title ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Aadi, LLC
Indications

colorectal cancer

Therapies

Bevacizumab + Fluorouracil + Leucovorin + Nab-rapamycin + Oxaliplatin

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.